Autonomic Phenotype Before and After Akt Inhibition: Akt Therapy for Melanoma Sub-study
N/A
18 Years
80 Years
18 Years
80 Years
Open (Enrolling)
Both
Diagnosis of Melanoma
Both
Diagnosis of Melanoma
Trial Information
Autonomic Phenotype Before and After Akt Inhibition: Akt Therapy for Melanoma Sub-study
Inclusion Criteria:
- Diagnosed with melanoma with a BRAF mutation and relapse following therapy with a
BRAF inhibitor
- Enrolled in a clinical trial through the Vanderbilt Ingram Cancer Center (VICC)
including an arm with an oral Akt inhibitor
- Able and willing to provide informed consent
Exclusion Criteria:
- Factors which in the investigator's opinion would prevent the participant from
completing the protocol, including poor compliance during previous studies or an
unpredictable schedule
- Unable to give informed consent
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
Drop in systolic blood pressure before and after Akt treatment
Outcome Time Frame:
8 hours
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
120390
NCT ID:
NCT01593579
Start Date:
May 2012
Completion Date:
May 2016
Related Keywords:
- Diagnosis of Melanoma
- melanoma
- autonomic failure
- hypotension
- akt therapy
- Melanoma
Name | Location |
|---|---|
| Vanderbilt University | Nashville, Tennessee 37232-6305 |
